Description

Irinotecan Vista for Infusions 20 mg/ml. 5 ml/100 mg Vial

Ingredients:

Irinotecan Vista contains irinotecan hydrochloride trihydrate as the active ingredient.

Dosage:

The recommended dosage of Irinotecan Vista for infusion is determined by a healthcare provider based on individual factors such as body surface area and the specific condition being treated.

Indications:

Irinotecan Vista is indicated for the treatment of colorectal cancer and other solid tumors.

Contraindications:

Irinotecan Vista is contraindicated in patients with a known hypersensitivity to irinotecan or any of the excipients in the formulation.

Directions:

Irinotecan Vista should be administered by a healthcare professional experienced in the use of cancer chemotherapeutic agents.

Pharmacological Effects:

Irinotecan Vista is a topoisomerase I inhibitor that interferes with DNA replication and cell division, ultimately leading to cell death. It is an important component of many chemotherapy regimens for solid tumors.

Clinical Trials:

Studies have shown that Irinotecan Vista, when used in combination with other chemotherapy agents, can significantly improve progression-free survival in patients with advanced colorectal cancer.

Additional Information:

It is important to monitor patients receiving Irinotecan Vista for signs of neutropenia, diarrhea, and other potential adverse reactions.